Holen Sie sich die Stockscreener-App
61.87
1.20%
-0.75
Handel nachbörslich:
61.79
-0.08
-0.13%
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Odyssean, LLC's Vaxcyte Inc(PCVX) Holding History - GuruFocus
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research - MarketBeat
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline - DirectorsTalk Interviews
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock - Stock Titan
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
PCVX SWOT Analysis: Key Financial Insights Revealed in 10-Q Fili - GuruFocus
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares - marketbeat.com
Vaxcyte (PCVX) Advances Phase 3 Trials Amid Mixed Market Signals - GuruFocus
Vaxcyte, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock - MarketBeat
Vaxcyte Q2 net loss widens on higher expenses - TradingView
Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingView
PCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingView
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M - TradingView
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. SEC Filing (Aug 5, 2026) - Stock Titan
BRIEF-Vaxcyte Q2 Operating Expenses USD 302.777 Million - TradingView
Press Release: Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
PCVX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking The 101.55% Potential Upside - DirectorsTalk Interviews
PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale - Stock Titan
Current ratio of Vaxcyte, Inc. – XETR:5VA - TradingView
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Liquidity Mapping Around (PCVX) Price Events - Stock Traders Daily
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP - MarketBeat
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vaxcyte (PCVX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Vaxcyte (NASDAQ:PCVX) CEO Grant Pickering Sells 16,198 Shares of Stock - MarketBeat
Grant Pickering (PCVX) outlines 18,198-share sale and recent June stock trades - Stock Titan
PCVX|Vaxcyte Inc|Price:55.720|Chg%:+1.060 - TradingKey
Vaxcyte Inc (PCVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vaxcyte, Inc. (PCVX) Stock Analysis: A 99% Potential Upside in a Clinical-Stage Vaccine Innovator - DirectorsTalk Interviews
First Light Asset Management LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Vaxcyte Inc (PCVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):